Sharks give a handle to potent anti-tumor multiparatopic antibodies inducing membrane depletion of PD-L1

被引:0
|
作者
Wozniak-Knopp, Gordana [1 ,2 ]
Natale, Veronica [1 ,2 ]
机构
[1] BOKU Univ, Inst Mol Biotechnol, Dept Biotechnol, Vienna, Austria
[2] Acib GmbH Austrian Ctr Ind Biotechnol, Graz, Austria
关键词
D O I
10.1016/j.chembiol.2024.04.008
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Despite the immense clinical success of the antibody therapeutics that neutralize programmed death receptor ligand 1 (PD -L1) and thus resurrect T cell antitumor activity, the patient response rates remain low. In this issue of Cell Chemical Biology , Ludwig et al. 1 reveal novel topologies of multiparatopic antibodies that mediate potent PD -L1 downregulation.
引用
收藏
页码:833 / 834
页数:2
相关论文
共 50 条
  • [21] Targeting the intrinsic signaling of PD-L1 in human monocytes by a novel PD-L1 antibody to promote anti-tumor immunity.
    Hsu, Michelle A.
    Liu, Xin
    Barham, Whitney
    Hirdler, Jacob
    Mao, Zhiming
    Lucien, Fabrice
    Dong, Haidong
    JOURNAL OF IMMUNOLOGY, 2023, 210 (01):
  • [22] A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity
    Albu, Diana I.
    Wolf, Benjamin J.
    Qin, Yan
    Wang, Xianzhe
    Ulumben, Amy Daniel
    Su, Mei
    Li, Vivian
    Ding, Eirene
    Gonzalo, Jose Angel
    Kong, Jason
    Jadhav, Ruturaj
    Kuklin, Nelly
    Visintin, Alberto
    Gong, Bing
    Schuetz, Thomas J.
    ONCOIMMUNOLOGY, 2024, 13 (01):
  • [23] Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity
    Sam, Johannes
    Colombetti, Sara
    Fauti, Tanja
    Roller, Andreas
    Biehl, Marlene
    Fahrni, Linda
    Nicolini, Valeria
    Perro, Mario
    Nayak, Tapan
    Bommer, Esther
    Schoenle, Anne
    Karagianni, Maria
    Le Clech, Marine
    Steinhoff, Nathalie
    Klein, Christian
    Umana, Pablo
    Bacac, Marina
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [24] SPECT/CT imaging of tumor PD-L1 expression using radiolabeled anti-PD-L1 antibodies
    Heskamp, Sandra
    Hobo, Willemijn
    Molkenboer-Kuenen, Janneke
    Olive, Daniel
    Oyen, Wim
    Dolstra, Harry
    Boerman, Otto
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (03)
  • [25] Anti-tumor immunotherapy by blockade of the PD-1/PD-L1 pathway with recombinant human PD-1-IgV
    Zhang, C.
    Wu, S.
    Xue, X.
    Li, M.
    Qin, X.
    Li, W.
    Han, W.
    Zhang, Y.
    CYTOTHERAPY, 2008, 10 (07) : 711 - 719
  • [26] Anti-Tumor Efficacy of Anti-PD-1/PD-L1 Antibodies in Combination With Other Anticancer Drugs in Solid Tumors: A Systematic Review and Meta-Analysis
    Inoue, Takashi
    Narukawa, Mamoru
    CANCER CONTROL, 2022, 29
  • [27] CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity
    Sullivan, Kathleen M. C.
    Vilalta, Marta
    Ertl, Linda S.
    Wang, Yu
    Dunlap, Carolyn
    Ebsworth, Karen
    Zhao, Bin N.
    Li, Shijie
    Zeng, Yibin
    Miao, Zhenhua
    Fan, Pingchen
    Mali, Venkat
    Lange, Christopher
    McMurtrie, Darren
    Yang, Ju
    Lui, Rebecca
    Scamp, Ryan
    Chhina, Vicky
    Kumamoto, Alice
    Yau, Simon
    Dang, Ton
    Easterday, Ashton
    Liu, Shirley
    Miao, Shichang
    Charo, Israel
    Schall, Thomas J.
    Zhang, Penglie
    PLOS ONE, 2023, 18 (06):
  • [28] FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis (vol 28, pg 285, 2015)
    Dahan, Rony
    Sega, Emanuela
    Engelhardt, John
    Selby, Mark
    Korman, Alan J.
    Ravetch, Jeffrey V.
    CANCER CELL, 2015, 28 (04) : 543 - 543
  • [29] KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC
    Li, Jinghan
    Shi, Daiwang
    Li, Siyi
    Shi, Xiang
    Liu, Yu
    Zhang, Yi
    Wang, Gebang
    Zhang, Chenlei
    Xia, Tian
    Piao, Hai-long
    Liu, Hong-Xu
    CELL DEATH & DISEASE, 2024, 15 (02)
  • [30] S-allylmercaptocysteine promotes anti-tumor immunity by suppressing PD-L1 expression
    Zhao, Zhongxi
    Wei, Guangwei
    Zhao, Jianxiong
    Sun, Yueyue
    Gao, Peng
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 161